These thematic networks address major public health needs, in fields as varied as maternal health, intensive care, infectiology, mycobacterial infections, pneumology and amyloidosis.

Made possible by the massification of clinical data and advances in artificial intelligence (AI), these approaches could profoundly transform the conduct of clinical trials in the years to come.

At a time when Parkinson's disease affects almost 11 million people worldwide, and its prevalence could more than double by 2050, the NS-PARK clinical research network is launching Master Trial, the first French clinical trial platform dedicated to neurodegenerative diseases. This innovative project aims to accelerate the identification of neuroprotective treatments for Parkinson's disease by simultaneously testing several promising drug candidates.

The French EVERDAC trial, conducted in nine intensive care units through the CRICS-TRIGGERSEP network, which specializes in critical care and sepsis and is F-CRIN certified, shows that it is possible to delay the placement of an arterial catheter in patients in shock without compromising their chances of survival and with fewer local complications.